What is B. Riley's Forecast for Altimmune FY2024 Earnings?

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at B. Riley reduced their FY2024 EPS estimates for shares of Altimmune in a research note issued to investors on Wednesday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($1.40) for the year, down from their prior estimate of $1.96. B. Riley has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune's Q4 2024 earnings at ($0.39) EPS, Q2 2025 earnings at $2.33 EPS, Q3 2025 earnings at ($0.54) EPS and Q4 2025 earnings at ($0.64) EPS.

ALT has been the topic of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday. Evercore ISI upgraded Altimmune to a "strong-buy" rating in a research report on Friday, August 9th. Finally, UBS Group started coverage on Altimmune in a research report on Tuesday. They issued a "buy" rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $20.00.

Altimmune Trading Down 10.0 %

Shares of ALT stock traded down $0.84 on Friday, reaching $7.61. 5,390,865 shares of the company's stock were exchanged, compared to its average volume of 3,871,940. The stock has a market capitalization of $541.22 million, a PE ratio of -4.91 and a beta of 0.09. Altimmune has a 52 week low of $2.34 and a 52 week high of $14.84. The company's fifty day simple moving average is $7.02 and its 200 day simple moving average is $6.91.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the previous year, the company posted ($0.39) EPS.

Hedge Funds Weigh In On Altimmune

Several large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Altimmune during the 1st quarter worth $271,000. BNP Paribas Financial Markets grew its holdings in shares of Altimmune by 154.0% in the 1st quarter. BNP Paribas Financial Markets now owns 32,425 shares of the company's stock worth $330,000 after purchasing an additional 19,661 shares during the last quarter. SG Americas Securities LLC raised its position in Altimmune by 68.3% in the 1st quarter. SG Americas Securities LLC now owns 39,603 shares of the company's stock valued at $403,000 after purchasing an additional 16,078 shares during the last quarter. Swiss National Bank bought a new position in shares of Altimmune in the first quarter worth about $1,079,000. Finally, Sei Investments Co. acquired a new position in Altimmune during the 1st quarter valued at about $479,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Insider Activity

In other news, Director David Drutz sold 16,011 shares of the company's stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares of the company's stock, valued at approximately $289,510.20. This represents a 27.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.